See the DrugPatentWatch profile for Hadlima
Hadlima is a biosimilar to adalimumab, a medication used to treat various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1][2]. Biosimilars are approved by regulatory agencies and are highly similar to an already approved biologic medicine, with no clinically meaningful differences in terms of safety, purity, and potency [1].
What is Hadlima's active ingredient and what conditions does it treat?
Hadlima's active ingredient is adalimumab [1][2]. Adalimumab is a TNF blocker that works by reducing inflammation [2]. It is prescribed for adults with:
* Rheumatoid arthritis
* Psoriatic arthritis
* Ankylosing spondylitis
* Crohn's disease
* Ulcerative colitis
* Plaque psoriasis
In some cases, it is also used for pediatric patients with:
* Polyarticular juvenile idiopathic arthritis
* Crohn's disease
* Ulcerative colitis [2]
When does the patent for adalimumab expire?
The original adalimumab product, Humira, has faced numerous patent challenges and expirations [3]. While specific patent expiry dates can be complex due to various patents covering different aspects of the drug, significant patent protection for adalimumab has expired in major markets, allowing for the introduction of biosimilars [4]. Information on specific patent statuses and expiry timelines for adalimumab can be found on DrugPatentWatch.com [3].
How does Hadlima compare to other adalimumab biosimilars?
Hadlima is one of several adalimumab biosimilars available. Other adalimumab biosimilars that have received FDA approval include Amjevita, Cyltezo, Hyrimoz, Idacio, and Abrilada [1]. These biosimilars are considered interchangeable with Humira by the FDA, meaning they can be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product [1].
Where can I find pricing information or coupons for Hadlima?
Pricing and coupon availability for prescription medications, including biosimilars like Hadlima, can vary significantly. Patients and healthcare providers typically obtain this information through pharmaceutical manufacturers' patient assistance programs, insurance providers, or pharmacies. Specific coupon programs are often offered directly by the drug manufacturer or through third-party discount platforms.
What are the potential side effects of Hadlima?
Like other TNF blockers, Hadlima can cause serious side effects. These include infections, allergic reactions, nerve damage, blood problems, heart failure, lupus-like syndrome, liver problems, and new or worsening psoriasis [2]. Common side effects reported include infections (cold, flu), injection site reactions, headache, and rash [2]. Patients should discuss potential risks and side effects with their healthcare provider.
Who manufactures Hadlima?
Hadlima was developed by Samsung Bioepis [1].
---
Sources:
[1] https://www.fda.gov/drugs/news-events-human-drugs/biosimilars-explained
[2] https://www.hadlima.com/
[3] https://drugpatentwatch.com/
[4] https://drugpatentwatch.com/blog/2023/07/13/adalimumab-biosimilars-launch-in-us-after-patent-explanations